prevnar 13 pcv13  (Pfizer Inc)

Journal: Immunity, Inflammation and Disease

Article Title: Serotype 3 Streptococcus pneumoniae Escapes the Immune Responses Induced by PCV13 in Mice With High Susceptibility to Infection

doi: 10.1002/iid3.70062

Figure Lengend Snippet: PCV13 antibody responses and protection against pneumococcal infection. Anti‐PS3 (A) and anti‐PS1 (D) IgG levels were evaluated by ELISA in sera obtained 14 days after the third immunization of AIRmin, AIRmax and BALB/c mice (six per group) with PCV13 or saline. Dots indicate individual data, and bars indicate the means for each group with standard deviations. Dashed line indicates the limit of detection. Results are representative of three independent experiments. Survival curves of immunized AIRmin and BALB/c mice (5–6 per group) after the challenges with ST3 (B and C) or ST1 (E and F) pneumococcal strains. Survival was analyzed for 15 days. ** p < 0.01; *** p < 0.001; **** p < 0.0001, One‐way ANOVA with Tukey post‐test (A and D) and Log‐Rank survival curve with Mantel‐Cox test, B, C, E and F).

Article Snippet: Mice (4–6 per group, depending on the experiment) were immunized with 1/10 of the human dose of PCV13 (PREVNAR 13, Pfizer Inc., USA) and control groups received saline.

Techniques: Infection, Enzyme-linked Immunosorbent Assay, Saline

Journal: Immunity, Inflammation and Disease

Article Title: Serotype 3 Streptococcus pneumoniae Escapes the Immune Responses Induced by PCV13 in Mice With High Susceptibility to Infection

doi: 10.1002/iid3.70062

Figure Lengend Snippet: Bacterial colonization and neutrophil influx in the respiratory tract of mice immunized with PCV13. Mice (3–4 per group) received three doses of PCV13 or saline and were challenged 21 days after the last dose with the ST3 pneumococcal strain. BALFs were collected at 12 h (A and D) or 24 h (B, C and E) for the evaluation of bacterial colonization (A–C) or neutrophil influx (D and E). Neutrophil detection was performed by flow cytometry as the Ly6G + CD11b + population in 30,000 events counted. Data were analyzed with the FlowJo V10.1 software. Dots indicate individual data, and bars indicate the means for each group with standard deviations. Dashed lines indicate the limits of detection. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001, One‐way ANOVA with Tukey posttest.

Article Snippet: Mice (4–6 per group, depending on the experiment) were immunized with 1/10 of the human dose of PCV13 (PREVNAR 13, Pfizer Inc., USA) and control groups received saline.

Techniques: Saline, Flow Cytometry, Software

Journal: Immunity, Inflammation and Disease

Article Title: Serotype 3 Streptococcus pneumoniae Escapes the Immune Responses Induced by PCV13 in Mice With High Susceptibility to Infection

doi: 10.1002/iid3.70062

Figure Lengend Snippet: IgG binding to the surface of ST3 and ST1 pneumococcal strains. Pneumococcal strains ATCC6301 (ST1) or 3JYP2670 (ST3) were incubated with pooled sera from mice immunized with three doses of PCV13 or saline, followed by incubation with anti‐mouse IgG conjugated to FITC. Binding was detected by flow cytometry with 15,000 events recorded. Data were analyzed with the FlowJo V10.1 software and graphs were produced with data from two experiments using sera from independent immunization experiments. Solid lines represent one experiment and dashed lines represent the other. All data were produced using 1% sera except experiment 2 (dashed line) for ATCC6301 that used 5% sera. Numbers indicate the MFI for each curve.

Article Snippet: Mice (4–6 per group, depending on the experiment) were immunized with 1/10 of the human dose of PCV13 (PREVNAR 13, Pfizer Inc., USA) and control groups received saline.

Techniques: Binding Assay, Incubation, Saline, Flow Cytometry, Software, Produced

Journal: Immunity, Inflammation and Disease

Article Title: Serotype 3 Streptococcus pneumoniae Escapes the Immune Responses Induced by PCV13 in Mice With High Susceptibility to Infection

doi: 10.1002/iid3.70062

Figure Lengend Snippet: Induction of pneumococcal opsonophagocytosis by sera from mice immunized with PCV13. Sera from AIRmin, AIRmax and BALB/c mice (6 per pooled sera) immunized with three doses of PCV13 or saline were tested in opsonophagocytosis assays using J774 cells and ST3 (A) or ST1 (B) pneumococcal strains. Controls (Ctrl) contain all reaction components (cells, complement source and bacteria) except immune sera. Incubations were performed for 45 min and phagocytosis was considered significant when 50% reductions in CFU counting in relation to the control were observed (dashed line). Bars represent the mean with standard deviations. Graphs were composed with sera from two independent immunization experiments.

Article Snippet: Mice (4–6 per group, depending on the experiment) were immunized with 1/10 of the human dose of PCV13 (PREVNAR 13, Pfizer Inc., USA) and control groups received saline.

Techniques: Saline, Bacteria, Control

Journal: Immunity, Inflammation and Disease

Article Title: Serotype 3 Streptococcus pneumoniae Escapes the Immune Responses Induced by PCV13 in Mice With High Susceptibility to Infection

doi: 10.1002/iid3.70062

Figure Lengend Snippet: Agglutination of ST3 pneumococci by sera from mice (six per pooled sera) immunized with PCV13. The 3JYP2670 pneumococcal strain was incubated with different concentrations of pooled sera from AIRmin, AIRmax and BALB/c mice immunized with three doses of PCV13 or pre‐immune sera. Bacterial populations were selected based on forward scatter (FSC) and side scatter (SSC) parameters, with the acquisition of 200,000 events and data were analyzed with FlowJo V10.1 software. The numbers indicate the percentage of bacterial agglutinates. Results are representative of two assays with sera from independent immunization experiments (A). Sera from three independent pools (at a concentration of 40%) were compared for the ability to induce pneumococcal agglutination (B).

Article Snippet: Mice (4–6 per group, depending on the experiment) were immunized with 1/10 of the human dose of PCV13 (PREVNAR 13, Pfizer Inc., USA) and control groups received saline.

Techniques: Agglutination, Incubation, Software, Concentration Assay

Journal: Immunity, Inflammation and Disease

Article Title: Serotype 3 Streptococcus pneumoniae Escapes the Immune Responses Induced by PCV13 in Mice With High Susceptibility to Infection

doi: 10.1002/iid3.70062

Figure Lengend Snippet: Opsonophagocytosis of ST3 pneumococci by neutrophils from AIRmin, AIRmax and BALB/c mice in the presence of PCV13‐immune sera. Bone‐marrow derived neutrophils from AIRmin, AIRmax and BALB/c mice (4 per group) were compared for their phagocytic capacity against ST3 pneumococci (3JYP2670 strain) in the presence of sera from mice immunized with three doses of PCV13 or saline. Controls (Ctrl) contain all reaction components (neutrophils from each mice line, complement source and bacteria) except immune sera. Incubations were performed for 45 min and phagocytosis was considered significant when 50% reductions in CFU counting in relation to the respective controls were observed (dashed lines) and plating was performed in duplicates. Bars represent the mean for each group ( n = 4).

Article Snippet: Mice (4–6 per group, depending on the experiment) were immunized with 1/10 of the human dose of PCV13 (PREVNAR 13, Pfizer Inc., USA) and control groups received saline.

Techniques: Derivative Assay, Saline, Bacteria

Journal: Human Vaccines & Immunotherapeutics

Article Title: Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024

doi: 10.1080/21645515.2024.2417554

Figure Lengend Snippet: Serotypes covered by PCV7, PCV10, PCV13, PCV20, and PPSV23.

Article Snippet: Ltd., Pune, India), , the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar Ⓡ 13, Wyeth Pharmaceuticals Inc, Philadelphia, PA, USA), and the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax Ⓡ 23, Merck & Co Inc, Whitehouse Station, NJ, USA).

Techniques:

Journal: Human Vaccines & Immunotherapeutics

Article Title: Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024

doi: 10.1080/21645515.2024.2417554

Figure Lengend Snippet: Use of pneumococcal vaccines in NIPs.

Article Snippet: Ltd., Pune, India), , the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar Ⓡ 13, Wyeth Pharmaceuticals Inc, Philadelphia, PA, USA), and the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax Ⓡ 23, Merck & Co Inc, Whitehouse Station, NJ, USA).

Techniques: Vaccines